Plasma exchange is increasingly used for management of @entity4019 . However little is known about the long term effects of this treatment. Therefore we have reviewed the clinical and laboratory data of 20 @entity1 with type II EMC who were followed for a mean of 24 months. 16 @entity1 had @entity8 , which was characterized histologically in all of them: 9 had diffuse proliferative GN plus endoluminal "thrombi" in 6 and @entity1333 in 5, 4 had lobular membranoproliferative GN and 3 had focal proliferative GN. 14 @entity1 had @entity177 and 13 had @entity644 greater than or equal to 2 g/24 hr. PE (combined with immunosuppressive drugs in 18) was performed for a mean of 18 procedures. The combined treatment induced prompt remission of extrarenal and @entity8 . Serum @entity1011 and @entity644 decreased significantly in all but 2 @entity1 during the treatment (s. @entity1011 from 2.9 to 1.6 mg/dl; @entity644 from 3.5 to 1.6 g/24 hr). Analysis of long term follow up revealed that these effects were long lasting in all the cases. We conclude that PE should be used for EMC @entity8 whenever prompt remission is not obtained by conventional therapy especially in consideration of its long term beneficial effects.

Plasma exchange in the treatment of XXXX . Long-term follow up.

@entity4019 :: ('MESH:C565141', 'Disease') :: ['Essential Mixed Cryoglobulinemia'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy', 'renal involvement'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity1333 :: ('MESH:D014657', 'Disease') :: ['vasculitis'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']
@entity8 :: (MESH:D007674,Disease) :: ['essential mixed cryoglobulinemia nephropathy']
